Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 13/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305985 | 0.87 | PTPRB (0.39) | PTPRBPPARGPPARAATMAPP | |
| SCHEMBL4305986 | 0.87 | PTPRB (0.39) | PTPRBPPARGPPARAATMAPP | |
| SCHEMBL12056498 | 0.87 | PTPRB (0.37) | PTPRBPPARGPPARAATMALDH1A1 | |
| SCHEMBL12056496 | 0.84 | PPARG (0.36) | PTPRBPPARGPPARAATMAPP | |
| SCHEMBL4296618 | 0.83 | PTPRB (0.37) | PTPRBPPARGPPARAATMAPP | |
| SCHEMBL4296621 | 0.83 | PTPRB (0.37) | PTPRBPPARGPPARAATMAPP | |
| SCHEMBL4297420 | 0.80 | PPARA (0.35) | PTPRBPPARGPPARAATMALDH1A1 | |
| SCHEMBL4303579 | 0.79 | PPARG (0.39) | PTPRBPPARGPPARAATMAPP | |
| SCHEMBL4303581 | 0.79 | PPARG (0.39) | PTPRBPPARGPPARAATMAPP | |
| SCHEMBL13286159 | 0.78 | PTPRB (0.35) | PTPRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981884-B1 | THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS | AMGEN INC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8084479-B2 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20090270445-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7514566-B2 | Thiazole compounds and methods of use | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20070173506-A1 | Thiazole compounds and methods of use | AMGEN INC. (US) | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270445-A1 | Thiazole compounds and methods of use | MTOR, JAK2, TK2 | PTPRB 888/4885PPARG 185/4885PPARA 466/4885 |
| US-20070173506-A1 | Thiazole compounds and methods of use | MTOR, JAK2, PCK2 | PTPRB 598/4885PPARG 194/4885PPARA 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.